A Study of Risvutatug Rezetecan in Combination With Ivonescimab in Participants With Advanced Solid Tumors (EMBOLD PanTumour-103)
Neoplasms, Lung
No strong warning signs right now. The score counts warning signs; it is not a prediction.
Why this score
No warning signs right now. That's why the score is 0.
Score over time
- Stage
- Phase 1/2
- Patients
- 184 (planned)
- Started
- Sep 9, 2026
- Main results expected
- Jun 22, 2029
- Fully finished
- Dec 24, 2029
- Results posted
- not yet
What counts as success
The trial's main goal(s), called the “primary outcome.”
Phase 1 and Phase 2 Number of participants with Adverse events (AEs), Serious Adverse Events (SAEs) and Adverse events of special interest (AESIs)
Measured over: Up to approximately 143 weeks
Phase 1 and Phase 2: Number of participants with AEs leading to dose modifications including study intervention discontinuation
Measured over: Up to approximately 130 weeks
Phase 2: Number of participants with AEs leading to dose modifications or study intervention discontinuation
Measured over: Up to approximately 130 weeks
Phase 1 and Phase 2: Number of participants with changes in safety parameters
Measured over: Up to approximately 143 weeks
Phase 1: Number of participants with Dose Limiting Toxicities (DLT)
Measured over: Up to 21 days
Phase 1 and Phase 2: Number of participants with a change from baseline in vital signs
Measured over: Baseline (Day -1) and up to approximately 143 weeks
Phase 1 and Phase 2: Number of participants with a change from baseline in body weight
Measured over: Baseline (Day -1) and up to approximately 143 weeks
Phase 1 and Phase 2: Number of participants with a change from baseline in laboratory parameters (hematology, clinical chemistry and urinalysis)
Measured over: Baseline (Day -1) and up to approximately 143 weeks
Phase 1 and Phase 2: Number of participants with a change from baseline in cardiac function [Electrocardiogram (ECG) and Echocardiogram (ECHO)]
Measured over: Baseline (Day -1) and up to approximately 143 weeks
Phase 1 and Phase 2: Number of participants with a change from baseline in Eastern Cooperative Oncology Group (ECOG) performance status
Measured over: Baseline (Day -1) and up to approximately 143 weeks
Phase 2:Confirmed Objective Response Rate (cORR)
Measured over: Up to approximately 143 weeks
Changes Tremor has spotted
Show details (technical version)
Score inputs
- none
Raw record changes
- none yet
Trial ID NCT07602855 · record last updated 2026-09-23 · checked 2026-11-09 15:47 UTC